Plasma Exchange for Longevity: Evidence and Risks

What this means

Medical therapeutic plasma exchange (TPE) removes a patient’s plasma and replaces it with albumin or donor plasma to treat specific diseases. Longevity TPE uses similar hardware in well or mildly ill adults hoping to dilute “pro-aging” plasma factors. The machines can look identical. The evidence, ethics, and indication do not.

Interest comes from heterochronic parabiosis and from mouse work showing that replacing old plasma with saline plus albumin can improve muscle repair, liver fat and fibrosis, and hippocampal neurogenesis without young blood. A PMC paper reported that a single such “neutral” exchange reset aspects of the old mouse proteome and that human TPE serum briefly looked less inhibitory to progenitor cells in a dish. That is mechanistic speculation, not a public-health recommendation.

ASFA’s clinical categories still describe diseases, not birthday TPE. NHLBI and AAN describe TPE where it saves organ function or speeds neurologic recovery. Longevity TPE is speculative, costly, and not a proven aging treatment. Infection, clotting, hypocalcemia, and access complications remain the price of attaching an extracorporeal circuit.

What the evidence shows

Animal data: Conboy and colleagues showed old mice do not require young plasma for several rejuvenation readouts if plasma is diluted and albumin is returned. That undercuts “young donor blood” marketing more than it endorses a clinic package. Mice are not 70-year-old humans with coronary disease and a calendar of elective catheters.

Human data: a small randomized, placebo-controlled PMC study in adults over 50 compared monthly TPE, biweekly TPE, biweekly TPE plus IVIG, and sham. Investigators reported safety with few discontinuations and improvements in several epigenetic clocks versus placebo, with the TPE-plus-IVIG arm looking strongest on some composites. Sample size was about 40 people. Clinical outcomes such as disability, hospitalization, or survival were not established. Clock movement can reverse or attenuate; the paper discusses possible compensatory effects after repeated sessions. IVIG itself is a medical product with thrombosis and infusion risks, not a vitamin.

What remains unshown: that elective TPE should join statins, blood-pressure control, smoking cessation, vaccines, or cancer screening as standard preventive care. ASFA did not convert wellness aging into Category I. FDA regulates plasma and albumin as biologics, not as anti-aging drugs. Procedure-risk literature (ICU TPE reviews) still lists citrate hypocalcemia, catheter infection, thrombosis, hypotension, and plasma reactions.

Cost is part of the evidence picture because it shapes how often people repeat a speculative circuit. Cash packages can run into the five figures for a short series, without insurer review of indication. That spending can crowd out indicated care—sleep apnea treatment, statin adherence, or a delayed colonoscopy. A clock that looks younger on a slide does not offset a missed cancer screen or an infected catheter admission.

Common myths

Myth: Longevity TPE is just TTP treatment done earlier. Fact: TTP TPE uses donor plasma to supply ADAMTS13 in a hospital. Elective albumin dilution is a different recipe and a different goal.

Myth: Young plasma is required. Fact: Mouse dilution data argue the opposite. Buying “young FFP” as a luxury is not supported and adds transfusion risk.

Myth: Epigenetic age dropping two years means you will live two years longer. Fact: Clocks are surrogates. They can move with illness, drugs, and lab noise. They are not a life-table.

Myth: If it is safe enough for ICU patients, it is safe enough monthly for wellness. Fact: ICU patients accept TPE because the disease is worse than the line. A well person has the harms without that bargain. Repeated central access is not a hobby.

How clinics use it

Some cash-pay longevity programs sell TPE series with albumin, labs, and optional IVIG, citing mouse papers and clock studies. Sessions can cost thousands of dollars, with multi-visit packages. Coverage is usually absent. Staffing may lack overnight apheresis physicians. That structure is a business model, not an ASFA pathway.

Academic groups may run IRB-approved TPE aging studies. Those have inclusion criteria, sham arms, and stopping rules. Being a customer is not the same as being a participant. Ask which you are.

Honest clinics will say the indication is off the medical map, list infection and clotting risks, and will not claim to treat TTP, GBS, or hyperviscosity in a spa chair. If they use those diseases as social proof, leave. Medical TPE belongs with hematology and neurology.

Practical takeaway

Keep indicated TPE in hospitals for ASFA-aligned disease. Keep longevity TPE in the “early research, high cost, real harm” bin. If you still consider it, demand a licensed physician, a named product (albumin versus plasma), access plan, calcium monitoring, and after-hours coverage. Read the small randomized clock study as hypothesis-generating, not as a prescription.

Do not spend the preventive-care budget on elective circuits while blood pressure, sleep apnea, or tobacco go unmanaged. Do not donate plasma thinking it is TPE, and do not use TPE thinking it is donation. Do not add IVIG to a wellness exchange because a clock arm looked better without understanding thrombosis and headache risk.

The adult decision is simple to state and hard to sell: TPE is a hospital-class procedure. For aging, evidence is animal and early human speculation. Harms and cost are present tense. It is not standard preventive care. If you enroll in a trial, keep a copy of the consent, the sham design, and the stopping rules. If you are only a customer, you are paying for extrapolation. That can be a legal purchase and still be a poor medical bargain.